Murray Brunt, MBBS on 10-Year Results of FAST: 5-Fraction RT for Breast Cancer

Ten-year results from the FAST study show that there are no significant differences in normal tissue effects (NTE) rates after 28.5 Gy/5 fractions (fr) compared with 50 Gy/25 fr in patients with early breast cancer; however, NTE were higher with 30 Gy/5 fr, according to a study published in the Journal of Clinical Oncology. In an interview with i3 Health, Murray Brunt, MBBS, FRCP, FRCR, lead study author, provides insights on the significance of these results and how treatment will evolve in the...
Continue reading

Palbociclib for Early Breast Cancer

A phase 2 clinical trial assessing the feasibility of adjuvant palbociclib (IbranceĀ®, Pfizer) and endocrine therapy for patients with early breast cancer reports that it is an effective treatment for these patients. Palbociclib, a targeted therapy drug that inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), causes the cancerous cells to stop dividing and reproducing, ultimately stopping cancer growth. This drug has already been approved for advanced metastatic breast cancer. For the study, publ...
Continue reading

Copyright Ā© 2020 i3 Health. All rights reserved.